Rhumbline Advisers Pmv Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.51 - $2.21 $59,936 - $87,721	-39,693 Reduced 63.28%	23,035 $37,000
Q1 2024 May 09, 2024	BUY	$1.51 - $3.12 $4,499 - $9,297	2,980 Added 4.99%	62,728 $106,000
Q4 2023 Feb 08, 2024	SELL	$1.23 - $6.6 $2,024 - $10,863	-1,646 Reduced 2.68%	59,748 $185,000
Q3 2023 Nov 09, 2023	BUY	$6.01 - $8.93 $480 - $714	80 Added 0.13%	61,394 $376,000
Q2 2023 Aug 08, 2023	BUY	$3.94 - $6.27 $13,065 - $20,791	3,316 Added 5.72%	61,314 $383,000
Q1 2023 May 11, 2023	BUY	$4.77 - $9.16 $7,555 - $14,509	1,584 Added 2.81%	57,998 $277,000
Q4 2022 Feb 14, 2023	BUY	$8.17 - $12.95 $6,168 - $9,777	755 Added 1.36%	56,414 $491,000
Q3 2022 Nov 10, 2022	BUY	$11.4 - $17.18 $32,353 - $48,756	2,838 Added 5.37%	55,659 $662,000
Q2 2022 Aug 11, 2022	BUY	$9.23 - $22.43 $231,959 - $563,688	25,131 Added 90.76%	52,821 $753,000
Q1 2022 May 12, 2022	BUY	$14.86 - $23.55 $29,467 - $46,699	1,983 Added 7.71%	27,690 $577,000
Q4 2021 Feb 10, 2022	BUY	$19.99 - $30.24 $17,911 - $27,095	896 Added 3.61%	25,707 $594,000
Q3 2021 Nov 12, 2021	BUY	$26.84 - $36.58 $33,737 - $45,981	1,257 Added 5.34%	24,811 $739,000
Q2 2021 Aug 05, 2021	BUY	$28.01 - $36.01 $267,103 - $343,391	9,536 Added 68.03%	23,554 $805,000
Q1 2021 May 06, 2021	BUY	$30.66 - $49.5 $2,759 - $4,455	90 Added 0.65%	14,018 $461,000
Q4 2020 Feb 10, 2021	BUY	$31.86 - $61.51 $443,746 - $856,711	13,928 New	13,928 $857,000

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.